The top European drug regulator has recommend approval of a Novartis AG (NVS) drug that would be the first vaccine against meningitis B, a brain inflammation that mostly attacks children, killing about 8% and leaving others with brain damage. Novartis is also seeking to test the vaccine in the U.S. There are five types of meningitis, with vaccines for the other four. In Europe, type B is the most common, causing 3,000-5,000 cases a year. Shares rose 0.1%.